These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 35200571

  • 1. A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.
    Lim CA, Banyi N, Tucker T, Ionescu DN, Melosky B.
    Curr Oncol; 2022 Feb 03; 29(2):848-852. PubMed ID: 35200571
    [Abstract] [Full Text] [Related]

  • 2. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
    Hayashi N, Fujita A, Saikai T, Takabatake H, Sotoshiro M, Sekine K, Kawana A.
    Intern Med; 2018 Mar 01; 57(5):713-716. PubMed ID: 29151522
    [Abstract] [Full Text] [Related]

  • 3. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
    Gonzalez-Mosquera LF, Rous FA, Rogers A, Smith N, Goyert G, Gadgeel S.
    Clin Lung Cancer; 2024 Mar 01; 25(2):e77-e80. PubMed ID: 38057186
    [Abstract] [Full Text] [Related]

  • 4. Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib.
    Zhang Y, Qin Y, Xu H, Yao Q, Gao Y, Feng Y, Ren J.
    Pathol Oncol Res; 2021 Mar 01; 27():637745. PubMed ID: 34257603
    [Abstract] [Full Text] [Related]

  • 5. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S, Shi C, Zhang H, Li J.
    Medicine (Baltimore); 2021 Dec 23; 100(51):e27999. PubMed ID: 34941039
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
    Koyama K, Katsurada N, Jimbo N, Tachihara M, Tamura D, Nakata K, Nagano T, Yamamoto M, Kamiryo H, Kobayashi K, Itoh T, Nishimura Y.
    Pathol Int; 2019 May 23; 69(5):294-299. PubMed ID: 30900377
    [Abstract] [Full Text] [Related]

  • 8. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel KIF5B-ALK Fusion Oncokinase.
    Shimizu N, Akashi Y, Fujii T, Shiono H, Yane K, Kitahara T, Ohta Y, Kakudo K, Wakasa T.
    Anticancer Res; 2019 Jan 23; 39(1):413-420. PubMed ID: 30591488
    [Abstract] [Full Text] [Related]

  • 9. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N, Nakashima K, Naito T, Nakajima T, Endo M, Takahashi T.
    BMC Cancer; 2017 Jul 06; 17(1):471. PubMed ID: 28683775
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.
    Lin X, Yang X, Tan Y, Duan Q, He M.
    Invest New Drugs; 2022 Oct 06; 40(5):1160-1163. PubMed ID: 35608716
    [Abstract] [Full Text] [Related]

  • 12. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M, Kubotaa M, Harada S, Niwa H, Kusuhara S, Kasajima M, Hiyoshi Y, Ishihara M, Igawa S, Masuda N.
    Lung Cancer; 2016 Sep 06; 99():66-8. PubMed ID: 27565916
    [Abstract] [Full Text] [Related]

  • 13. [Alectinib and mixed large cell neuroendocrine carcinoma of the lung.].
    Hegedűs F, Sükösd F, Tiszlavicz L, Furák J, Pálföldi R, Fejes Z, Zombori T.
    Orv Hetil; 2023 Apr 09; 164(14):548-554. PubMed ID: 37031440
    [Abstract] [Full Text] [Related]

  • 14. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
    Lin J, Wang W, Lin J, Chen R, Cao Y.
    J Cell Mol Med; 2022 Oct 09; 26(20):5326-5329. PubMed ID: 36102237
    [Abstract] [Full Text] [Related]

  • 15. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S, Li Q, Peng W, Feng C, Zhang S, Li C.
    J Thorac Oncol; 2018 May 09; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y, Inomata S, Yamaguchi H, Mine H, Takagi H, Watanabe M, Ozaki Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Hasegawa T, Shio Y, Suzuki H.
    Thorac Cancer; 2021 Aug 09; 12(15):2225-2228. PubMed ID: 34159737
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma.
    Gadotti LL, Nogueira Amorim Canedo FS, Ribeiro MFSA, Sacardo KP, Saddi R, Machado Alessi JV, de Abreu Testagrossa L, Katz A.
    Clin Lung Cancer; 2021 May 09; 22(3):e481-e486. PubMed ID: 32771343
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.